NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 30 04:00PM ET
0.5413
Dollar change
+0.0004
Percentage change
0.07
%
Index- P/E- EPS (ttm)-0.38 Insider Own3.16% Shs Outstand245.40M Perf Week25.30%
Market Cap132.84M Forward P/E- EPS next Y-0.36 Insider Trans0.00% Shs Float237.64M Perf Month18.27%
Enterprise Value132.54M PEG- EPS next Q-0.02 Inst Own21.61% Short Float10.80% Perf Quarter-33.99%
Income-80.74M P/S2.08 EPS this Y25.18% Inst Trans-14.57% Short Ratio3.60 Perf Half Y-78.35%
Sales63.76M P/B24.86 EPS next Y3.03% ROA-75.06% Short Interest25.67M Perf YTD-46.93%
Book/sh0.02 P/C5.28 EPS next 5Y20.67% ROE-262.12% 52W High3.18 -82.97% Perf Year27.85%
Cash/sh0.10 P/FCF- EPS past 3/5Y26.70% 10.57% ROIC-271.09% 52W Low0.30 78.06% Perf 3Y-87.61%
Dividend Est.- EV/EBITDA- Sales past 3/5Y-19.48% -10.81% Gross Margin86.26% Volatility13.62% 10.14% Perf 5Y-94.37%
Dividend TTM- EV/Sales2.08 EPS Y/Y TTM79.41% Oper. Margin-128.52% ATR (14)0.05 Perf 10Y-95.27%
Dividend Ex-Date- Quick Ratio0.76 Sales Y/Y TTM239.92% Profit Margin-126.63% RSI (14)52.33 Recom1.71
Dividend Gr. 3/5Y- - Current Ratio0.76 EPS Q/Q48.97% SMA206.93% Beta1.24 Target Price4.10
Payout- Debt/Eq5.07 Sales Q/Q1238.25% SMA50-5.57% Rel Volume0.31 Prev Close0.54
Employees183 LT Debt/Eq5.07 EarningsMay 12 AMC SMA200-52.82% Avg Volume7.13M Price0.54
IPOApr 06, 2000 Option/ShortYes / Yes EPS/Sales Surpr.-19.35% -27.67% Trades Volume2,292,760 Change0.07%
Date Action Analyst Rating Change Price Target Change
Dec-13-24Upgrade Truist Hold → Buy $7
Dec-10-24Reiterated H.C. Wainwright Buy $10
Nov-03-23Downgrade RBC Capital Mkts Outperform → Sector Perform $6 → $2
Apr-28-23Downgrade BofA Securities Neutral → Underperform $5 → $1.50
Feb-27-23Upgrade Wedbush Neutral → Outperform $16
Jan-06-23Downgrade BofA Securities Buy → Neutral $8 → $5
Jun-13-22Resumed Wedbush Neutral $5
May-04-21Initiated RBC Capital Mkts Outperform $22
Jan-07-21Resumed Guggenheim Neutral $16
Jan-06-21Initiated Stifel Hold $16
Jun-24-25 08:05AM
May-13-25 01:01PM
12:14PM
May-12-25 06:26PM
06:23PM
05:55PM Loading…
05:55PM
04:53PM
04:00PM
May-08-25 09:15AM
May-06-25 04:35PM
08:30AM
May-05-25 10:00AM
May-01-25 10:01AM
Apr-28-25 04:31PM
Apr-04-25 02:57PM
04:01PM Loading…
Apr-03-25 04:01PM
Mar-18-25 09:00AM
03:01AM
Mar-17-25 05:10PM
04:20PM
04:01PM
Mar-06-25 04:05PM
Feb-06-25 08:05AM
Jan-07-25 11:32AM
Jan-02-25 07:03AM
Dec-31-24 11:52AM
11:18AM
10:34AM
10:23AM
09:56AM
09:55AM Loading…
09:55AM
09:14AM
08:30AM
06:38AM
Dec-30-24 04:15PM
02:56PM
Dec-20-24 04:37AM
Dec-19-24 02:30AM
02:30AM
Nov-19-24 04:15PM
Nov-13-24 09:49AM
02:16AM
Nov-12-24 05:15PM
04:09PM
04:01PM
Nov-04-24 04:15PM
Oct-23-24 07:45AM
Oct-22-24 08:05AM
Aug-07-24 01:24PM
04:32AM
Aug-06-24 05:35PM
04:37PM
04:01PM
08:11AM
08:05AM
Jul-30-24 04:15PM
Jul-24-24 06:55AM
May-12-24 08:28AM
May-10-24 03:58PM
May-09-24 08:58PM
05:25PM
04:23PM
04:01PM
10:46AM
08:05AM
May-02-24 04:15PM
Apr-22-24 04:35PM
Mar-22-24 08:05AM
Mar-14-24 07:23AM
Mar-13-24 08:21AM
08:05AM
08:01AM
Mar-12-24 06:30PM
Feb-12-24 08:05AM
Feb-05-24 06:01PM
Nov-03-23 05:03PM
Nov-02-23 08:15AM
Nov-01-23 07:05PM
04:13PM
04:01PM
Oct-26-23 10:02AM
Oct-25-23 04:15PM
Oct-24-23 02:01AM
Sep-20-23 04:15PM
Aug-25-23 01:38PM
Aug-08-23 05:30PM
04:26PM
04:01PM
Aug-01-23 04:15PM
Jul-20-23 08:05AM
Jul-19-23 07:08AM
Jul-17-23 08:05AM
Jun-29-23 08:05AM
Jun-28-23 09:20AM
Jun-14-23 08:16AM
May-22-23 08:05AM
May-18-23 07:04AM
May-16-23 08:00AM
May-02-23 04:30PM
06:03AM
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.